{"id":1674,"date":"2023-06-25T17:29:32","date_gmt":"2023-06-25T17:29:32","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/bicalutamide\/"},"modified":"2023-06-25T19:50:26","modified_gmt":"2023-06-25T19:50:26","slug":"bicalutamide","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/bicalutamide\/","title":{"rendered":"Bicalutamide"},"content":{"rendered":"

<\/p>\n

Bicalutamide<\/h1>\n

CLINICAL USE<\/h3>\n

Treatment of prostate cancer<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

50\u2013150 mg daily(with orchidectomy or gonadorelin therapy)<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :430.4<\/li>\n
  • %Protein binding                           :96<\/li>\n
  • %Excreted unchanged in urine     : approx 50<\/li>\n
  • Volume of distribution (L\/kg)       :No data<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :6\u20137 days\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :Unknown dialysability. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      :Unlikely to be dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugsCisapride: avoid concomitant use See \u2018Other Information\u2019<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • In vitro studies have shown that bicalutamide is an inhibitor of CYP450 3A4. For drugs eliminated by this route, e.g. ciclosporin, tacrolimus, sirolimus, it is recommended that plasma concentrations and clinical condition be monitored following initiation or cessation of bicalutamide therapy<\/li>\n","protected":false},"excerpt":{"rendered":"

    Bicalutamide CLINICAL USE Treatment of prostate cancer DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1674","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1674"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1674\/revisions"}],"predecessor-version":[{"id":2893,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1674\/revisions\/2893"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}